AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35410913 — intervention group
Group type: EXPERIMENTAL
Intervention: FFR value
Number of subjects: 430
Study 35410913 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased HMR
Number of subjects: 430
Study 35410928 — intervention group
Group type: EXPERIMENTAL
Intervention: Swahili language Ada Symptom Assessment Application (SAA) used before usual care.
Number of subjects: 0
Study 35410928 — intervention group
Group type: COMPARATOR
Intervention: Usual care provided by healthcare practitioners after using the SAA.
Number of subjects: 0
Study 35411075 — intervention group
Group type: EXPERIMENTAL
Intervention: valoctocogene roxaparvovec (AAV5-hFVIII-SQ)
Number of subjects: 5
Study 35411113 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerenkov luminescence imaging (CLI)
Number of subjects: 0
Study 35411113 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care nuclear imaging
Number of subjects: 0
Study 35411349 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab plus standard of care
Number of subjects: 40
Study 35411349 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard of care
Number of subjects: 40
Study 35412071 — intervention group
Group type: EXPERIMENTAL
Intervention: Polytraumatized patients over time
Number of subjects: 953
Study 35412069 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron treatment for UUI
Number of subjects: 83
Study 35412216 — intervention group
Group type: EXPERIMENTAL
Intervention: batoclimab 680 mg
Number of subjects: 30
Study 35412216 — intervention group
Group type: EXPERIMENTAL
Intervention: batoclimab 340 mg
Number of subjects: 30
Study 35412216 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 35412216 — intervention group
Group type: EXPERIMENTAL
Intervention: batoclimab groups
Number of subjects: 30
Study 35412356 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesylate 200 mg dosed four times daily
Number of subjects: 0
Study 35412356 — intervention group
Group type: EXPERIMENTAL
Intervention: Camostat mesylate at 3-fold higher dosing
Number of subjects: 0
Study 35412607 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating tumor DNA
Number of subjects: 0
Study 35412607 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid biopsies
Number of subjects: 0
Study 35412950 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolation and culture protocols for hAMSCs
Number of subjects: 0
Study 35413027 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft contact lenses
Number of subjects: 294
Study 35413092 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim (1 μg/kg titrated to 10 μg/kg, administered weekly)
Number of subjects: 203
Study 35413092 — intervention group
Group type: EXPERIMENTAL
Intervention: Romiplostim
Number of subjects: 203
Study 35413279 — intervention group
Group type: EXPERIMENTAL
Intervention: Defibrotide (6.25 mg/kg/dose IV q6h) for 7 days
Number of subjects: 12
Study 35413473 — intervention group
Group type: EXPERIMENTAL
Intervention: Reliever use before and after exacerbations
Number of subjects: 0
Study 35413779 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography (MVUS) with MVUS-VI cutoff value of 24.95%
Number of subjects: 101
Study 35413779 — intervention group
Group type: COMPARATOR
Intervention: Conventional color Doppler (CD)
Number of subjects: 101
Study 35413779 — intervention group
Group type: COMPARATOR
Intervention: Power Doppler (PD)
Number of subjects: 101
Study 35413779 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography (MVUS)
Number of subjects: 101
Study 35413779 — intervention group
Group type: EXPERIMENTAL
Intervention: Microvascular ultrasonography vascularity indices (MVUS-VI)
Number of subjects: 101
Study 35413779 — intervention group
Group type: EXPERIMENTAL
Intervention: MVUS
Number of subjects: 101
Study 35413779 — intervention group
Group type: EXPERIMENTAL
Intervention: MVUS-VI
Number of subjects: 101
Study 35413789 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated NT-proCNP
Number of subjects: 309
Study 35413789 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP
Number of subjects: 309
Study 35413789 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proCNP
Number of subjects: 309
Study 35413789 — intervention group
Group type: EXPERIMENTAL
Intervention: STS-Score
Number of subjects: 309
Study 35413794 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT ≥14 ng/L
Number of subjects: 5199
Study 35413794 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnT <14 ng/L
Number of subjects: 5199
Study 35413794 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP ≥300 pg/ml
Number of subjects: 5199
Study 35413794 — intervention group
Group type: COMPARATOR
Intervention: NT-proBNP <300 pg/ml
Number of subjects: 5199
Study 35413794 — intervention group
Group type: EXPERIMENTAL
Intervention: Both hs-cTnT ≥14 ng/L and NT-proBNP ≥300 pg/ml
Number of subjects: 5199
Study 35413865 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly adults with SSD (measured by Somatic Symptom Scale-China)
Number of subjects: 6814
Study 35413865 — intervention group
Group type: EXPERIMENTAL
Intervention: Elderly adults with SSD
Number of subjects: 6814
Study 35413865 — intervention group
Group type: COMPARATOR
Intervention: Non-elderly adults (2206 participants)
Number of subjects: 6814
Study 35413904 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyScan Go device
Number of subjects: 2250
Study 35413904 — intervention group
Group type: EXPERIMENTAL
Intervention: EasyScan Go device with good quality slides
Number of subjects: 2250
Study 35413976 — intervention group
Group type: EXPERIMENTAL
Intervention: ParTNerSTEPs program (comprehensive transfer program for parents)
Number of subjects: 0
Study 35413985 — intervention group
Group type: EXPERIMENTAL
Intervention: Myeloablative conditioning with thiotepa-busulfan-fludarabine
Number of subjects: 101
Study 35414025 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule compounds targeting regulated cell death (RCD) subroutines, including narciclasine, torin-1 combined with chloroquine, ONC201, and NCT03733119.
Number of subjects: 0
Study 35414591 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoblituzumab (15 mg/kg) plus pembrolizumab (2 mg/kg) every 3 weeks
Number of subjects: 133
Study 35415385 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced food bank intervention
Number of subjects: 0
Study 35415385 — intervention group
Group type: COMPARATOR
Intervention: Standard food bank services
Number of subjects: 0
Study 35415708 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention from phase 3 randomized trials (LIBERTY 1 and 2)
Number of subjects: 30
Study 35415707 — intervention group
Group type: EXPERIMENTAL
Intervention: One Key Question (OKQ) implementation
Number of subjects: 0
Study 35415885 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D) subjects undergoing severe iatrogenic hypoglycaemia
Number of subjects: 46
Study 35415928 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose tissue-derived stem cells (ADSCs)
Number of subjects: 12
Study 35416053 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab maintenance treatment plus best supportive care
Number of subjects: 700
Study 35416053 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care alone
Number of subjects: 700
Study 35416669 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor and palbociclib
Number of subjects: 0
Study 35416710 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurtimox (NF) treatment
Number of subjects: 289
Study 35416787 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic rehabilitation table with serious games (12 sessions)
Number of subjects: 2
Study 35416975 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 35417089 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiographic red flags for AC (apical sparing or a combination of ≥2 other red flags)
Number of subjects: 217
Study 35417089 — intervention group
Group type: EXPERIMENTAL
Intervention: Final diagnosis of amyloid cardiomyopathy (AC)
Number of subjects: 217
Study 35417089 — intervention group
Group type: EXPERIMENTAL
Intervention: Transthyretin-related AC (ATTR-AC)
Number of subjects: 217
Study 35417089 — intervention group
Group type: EXPERIMENTAL
Intervention: Light chain-related AC (AL-AC)
Number of subjects: 217
Study 35417425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative F io2 median of 0.46 (range 0.32-0.94)
Number of subjects: 6588
Study 35417425 — intervention group
Group type: COMPARATOR
Intervention: Controlled trials with 80% vs 30% oxygen
Number of subjects: 6588
Study 35417425 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative F io2 median of 0.46
Number of subjects: 6588
Study 35417530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of HDAC inhibitors (panobinostat or romidepsin) and ClpP activators (ONC206 and ONC212)
Number of subjects: 0
Study 35417530 — intervention group
Group type: EXPERIMENTAL
Intervention: ClpP activators (mutant ClpP Y118A, ONC206, ONC212)
Number of subjects: 0
Study 35417530 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of HDAC inhibitors and imipridones
Number of subjects: 0
Study 35417530 — intervention group
Group type: EXPERIMENTAL
Intervention: Knockdown of ClpP protease or ectopic expression of ClpP D190A mutant
Number of subjects: 0
Study 35417637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (200 mg once daily, 400 mg once daily, 300 mg twice daily, 400 mg twice daily)
Number of subjects: 60
Study 35417637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (400 mg twice daily)
Number of subjects: 60
Study 35417637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib (all dose levels)
Number of subjects: 60
Study 35417637 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilzabrutinib
Number of subjects: 60
Study 35417638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat (5 mg twice daily, with potential escalation to 20 or 50 mg twice daily)
Number of subjects: 80
Study 35417638 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitapivat
Number of subjects: 80
Study 35417638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 35417717 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium antimony tartrate (PAT)
Number of subjects: 0
Study 35417791 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pain severity
Number of subjects: 1461
Study 35417791 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased pain interference
Number of subjects: 1461
Study 35418030 — intervention group
Group type: EXPERIMENTAL
Intervention: SCC (squamous cell carcinoma)
Number of subjects: 1291
Study 35418030 — intervention group
Group type: EXPERIMENTAL
Intervention: AC (adenocarcinoma)
Number of subjects: 1291
Study 35418030 — intervention group
Group type: COMPARATOR
Intervention: Comparison between SCC and AC
Number of subjects: 1291
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Support for legalization of unspecified living kidney donation
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Acceptance of family member donating to a stranger
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief that bone-marrow transplant is safe
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Recognition of benefits of pre-donation tests
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to receive a kidney from another person
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Willingness to donate organs after death
Number of subjects: 62
Study 35418039 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear of organ trafficking
Number of subjects: 62
Study 35418107 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal testing outreach and patient navigation program
Number of subjects: 0
Study 35418107 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 35418154 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch antibiotics (e.g., ceftriaxone, ciprofloxacin)
Number of subjects: 920
Study 35418154 — intervention group
Group type: EXPERIMENTAL
Intervention: Watch antibiotics
Number of subjects: 920
Study 35418154 — intervention group
Group type: EXPERIMENTAL
Intervention: Access antibiotics
Number of subjects: 920
Study 35418159 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M (serum type I collagen degradation biomarker)
Number of subjects: 233
Study 35418159 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M in obese asthmatics (BMI > 30) with high neutrophil levels
Number of subjects: 233
Study 35418159 — intervention group
Group type: EXPERIMENTAL
Intervention: C1M in OVA mice with acute neutrophilic inflammation
Number of subjects: 233
Study 35418159 — intervention group
Group type: COMPARATOR
Intervention: C1M in mice treated with CP17 (neutrophil infiltration inhibitor)
Number of subjects: 233
Study 35418172 — intervention group
Group type: EXPERIMENTAL
Intervention: abatacept (ABA) + MTX
Number of subjects: 509
Study 35418172 — intervention group
Group type: COMPARATOR
Intervention: MTX
Number of subjects: 509
Study 35418195 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1highICOSLlow Secretory DCs
Number of subjects: 0
Study 35418195 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-L1lowICOSLhigh Helper DCs
Number of subjects: 0
Study 35418195 — intervention group
Group type: EXPERIMENTAL
Intervention: Secretory DCs
Number of subjects: 0
Study 35418260 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 1643
Study 35418329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pH modulator (VPM; Phexxi)
Number of subjects: 1330
Study 35418339 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) applied over three different sites in the dorsolateral prefrontal cortex
Number of subjects: 15
Study 35418339 — intervention group
Group type: COMPARATOR
Intervention: General linear model (GLM) analysis
Number of subjects: 15
Study 35418436 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 vaccine awareness and acceptance
Number of subjects: 4198
Study 35418436 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived effectiveness and safety of COVID-19 vaccines
Number of subjects: 4198
Study 35418436 — intervention group
Group type: EXPERIMENTAL
Intervention: Sociodemographic factors
Number of subjects: 4198
Study 35418459 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher physical activity
Number of subjects: 134
Study 35418509 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 65
Study 35418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearing face masks
Number of subjects: 6925
Study 35418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard wearing of face masks
Number of subjects: 6925
Study 35418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstandard wearing of face masks, longer time of face mask wearing, reduced outdoor time, decreased daily reading time, shortened visual display terminals time, dry environment
Number of subjects: 6925
Study 35418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, female sex, education, use of glasses and contact lenses, pre-existing dry eye
Number of subjects: 6925
Study 35418586 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults aged > 20 years
Number of subjects: 6925
Study 35418936 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt surgery
Number of subjects: 127
Study 35418936 — intervention group
Group type: COMPARATOR
Intervention: Physical exercise program
Number of subjects: 127
Study 35419605 — intervention group
Group type: EXPERIMENTAL
Intervention: Early infant probiotic supplementation
Number of subjects: 0
Study 35419605 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35419649 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus and Sunitinib
Number of subjects: 144
Study 35419649 — intervention group
Group type: COMPARATOR
Intervention: Usual pNET treatments (chemotherapies and somatostatin analogues)
Number of subjects: 144
Study 35419748 — intervention group
Group type: EXPERIMENTAL
Intervention: Perfusion CT and dual-energy CT (DECT) quantitative parameters
Number of subjects: 56
Study 35419748 — intervention group
Group type: EXPERIMENTAL
Intervention: Permeability surface-area product (PS)
Number of subjects: 56
Study 35420493 — intervention group
Group type: EXPERIMENTAL
Intervention: Tebipenem pivoxil hydrobromide (TBP-PI-HBr); specific dosage and duration not mentioned.
Number of subjects: 0
Study 35420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 weeks of intensive aerobic cycle training)
Number of subjects: 27
Study 35420578 — intervention group
Group type: COMPARATOR
Intervention: Pannexin 1 inhibition after training
Number of subjects: 27
Study 35420578 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 27
Study 35420586 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonimprovement group (n = 92)
Number of subjects: 148
Study 35420586 — intervention group
Group type: COMPARATOR
Intervention: Improvement group (n = 38)
Number of subjects: 148
Study 35420628 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib, 60 mg orally once daily until disease progression, unacceptable toxic effects, or withdrawal of consent.
Number of subjects: 23
Study 35420700 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interventions
Number of subjects: 8186
Study 35421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Jarvik 2000 device
Number of subjects: 150
Study 35421002 — intervention group
Group type: EXPERIMENTAL
Intervention: Cone-bearing group
Number of subjects: 150
Study 35421002 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 150
Study 35421085 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models using interview variables
Number of subjects: 1694
Study 35421085 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models using complementary exam variables
Number of subjects: 1694
Study 35421085 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine Learning models using mixed variables (interview and complementary exams)
Number of subjects: 1694
Study 35421219 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Number of subjects: 103
Study 35421228 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for ≤2 years
Number of subjects: 51
Study 35421231 — intervention group
Group type: EXPERIMENTAL
Intervention: HepaVac-101 (IMA970A and CV8102)
Number of subjects: 22
Study 35421287 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital medicine system, details on dosage and duration not available
Number of subjects: 0
Study 35421287 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study 35421548 — intervention group
Group type: EXPERIMENTAL
Intervention: Injured knees
Number of subjects: 118
Study 35421548 — intervention group
Group type: COMPARATOR
Intervention: Uninjured knees (contralateral knees)
Number of subjects: 118
Study 35421930 — intervention group
Group type: EXPERIMENTAL
Intervention: High degree-of-worry
Number of subjects: 2857
Study 35421930 — intervention group
Group type: COMPARATOR
Intervention: Low degree-of-worry
Number of subjects: 2857
Study 35421930 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental degree-of-worry scoring
Number of subjects: 2857
Study 35421962 — intervention group
Group type: EXPERIMENTAL
Intervention: Viniyoga, an individualized Yoga practice for 14 weeks
Number of subjects: 21
Study 35421966 — intervention group
Group type: EXPERIMENTAL
Intervention: Yathu Yathu intervention (community-based, peer-led SRH services including differentiated HTS and CSE)
Number of subjects: 0
Study 35421966 — intervention group
Group type: EXPERIMENTAL
Intervention: Social media (WhatsApp/Facebook) for delivering CSE and COVID-19 information
Number of subjects: 0
Study 35422096 — intervention group
Group type: EXPERIMENTAL
Intervention: Tisagenlecleucel
Number of subjects: 16
Study 35422132 — intervention group
Group type: EXPERIMENTAL
Intervention: CHW-delivered intervention
Number of subjects: 255
Study 35422242 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 702
Study 35422242 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 702
Study 35422531 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab monotherapy
Number of subjects: 152
Study 35422607 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal aflibercept injections (IVT-AFL) with sham laser
Number of subjects: 30
Study 35422607 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (IVT-AFL) with micropulse (MP) laser
Number of subjects: 30
Study 35422656 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative radiotherapy (RT)
Number of subjects: 12500
Study 35425788 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (800 mg/day) and EPA (25 mg/day) supplementation for 6 months
Number of subjects: 54
Study 35425788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 35425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased percentage of REM sleep (per 5%)
Number of subjects: 4490
Study 35425819 — intervention group
Group type: EXPERIMENTAL
Intervention: Total REM sleep time
Number of subjects: 4490
Study 35425895 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted fencing program
Number of subjects: 24
Study 35425895 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 24
Study 35425930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Number of subjects: 0
Study 35425930 — intervention group
Group type: COMPARATOR
Intervention: Standard high-carbohydrate diet combined with cytotoxic chemotherapy (nab-paclitaxel, gemcitabine, cisplatin)
Number of subjects: 0
Study 35425934 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-T2 intervention (smartphone-based just-in-time adaptive intervention)
Number of subjects: 0
Study 35425934 — intervention group
Group type: EXPERIMENTAL
Intervention: TTRP intervention
Number of subjects: 0
Study 35425934 — intervention group
Group type: COMPARATOR
Intervention: QuitGuide intervention
Number of subjects: 0
Study 35425934 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart-T2 intervention
Number of subjects: 0